H3B-6527
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Hepatocellular Carcinoma
Conditions
Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms, Hepatic Cancer, Hepatic Carcinoma
Trial Timeline
Dec 28, 2016 → Feb 23, 2022
NCT ID
NCT02834780About H3B-6527
H3B-6527 is a phase 1 stage product being developed by Eisai for Advanced Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02834780. Target conditions include Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma, Liver Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03424577 | Phase 1 | Completed |
| NCT02834780 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Hepatocellular Carcinoma